FOXO1 and HOXA5 are not known to be directly regulated by p53, but studies in several cancer types suggest that these transcription factors may have p53-independent pro-differentiation and pro-apoptotic functions that potentiate the effects of wildtype p53 loss [20, 21]. This evidence concerns the gene TP53 and cancer.